Concord Wealth Partners Invests $57,000 in IQVIA Holdings Inc. (NYSE:IQV)

Concord Wealth Partners acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 241 shares of the medical research company’s stock, valued at approximately $57,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board increased its stake in shares of IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after purchasing an additional 211,653 shares in the last quarter. Lazard Asset Management LLC increased its stake in IQVIA by 0.9% in the 1st quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock worth $825,416,000 after buying an additional 30,014 shares in the last quarter. Farallon Capital Management LLC raised its holdings in IQVIA by 3.1% during the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after acquiring an additional 86,870 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of IQVIA by 3.8% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock worth $634,927,000 after acquiring an additional 92,293 shares during the period. Finally, Capital Research Global Investors grew its position in shares of IQVIA by 7.2% during the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock worth $540,882,000 after purchasing an additional 143,533 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IQV has been the subject of several recent analyst reports. Barclays dropped their price target on IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research note on Tuesday, October 15th. Truist Financial cut their target price on shares of IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a research note on Monday, October 14th. Royal Bank of Canada started coverage on shares of IQVIA in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price target on the stock. JPMorgan Chase & Co. reduced their target price on IQVIA from $288.00 to $279.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. Finally, UBS Group increased their price target on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Five equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average price target of $267.27.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $217.54 on Tuesday. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The company has a market capitalization of $39.66 billion, a price-to-earnings ratio of 28.25, a PEG ratio of 2.09 and a beta of 1.49. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The firm’s 50-day moving average is $237.12 and its 200 day moving average is $230.29.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.